The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
PDE5 inhibitors – pharmacology and clinical applications 20 years after sildenafil discovery
Open accessAbstract
The discovery of the nitric oxide/cGMP pathway was the basis for our understanding of many normal physiological functions and the pathophysiology of several diseases. Since the discovery and introduction of sildenafil, inhibitors of PDE5 have been the first‐line therapy for erectile dysfunction (ED). The success of sildenafil in the treatment of ED stimulated research in the field of PDE5 inhibition and led to many new applications, such as treatment of lower urinary symptoms, and pulmonary arterial hypertension, which are now approved indications. However, PDE5 inhibitors have also been used in several other disorders not discussed in this review, and the fields of clinical use are increasing. In the present review, the pharmacological basis of the NO/cGMP pathway and the rationale and clinical use of PDE5 inhibitors in different diseases are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nitric oxide: physiology, pathophysiology, and pharmacology.
Moncada, S., Palmer, R. M., & Higgs, E. A. (1991) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06663-3 · Cited by 15,525
Furchgott, R. F., & Zawadzki, J. V. (1980) · Nature · doi:10.1038/288373a0 · Cited by 12,064
Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension
Galiè, N., Ghofrani, H. A., Torbicki, A., Barst, R. J., Rubin, L. J., Badesch, D., Fleming, T., Parpia, T., Burgess, G., Branzi, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050010 · Cited by 2,476
Oral Sildenafil in the Treatment of Erectile Dysfunction
Goldstein, I., Lue, T. F., Padma-Nathan, H., Rosen, R. C., Steers, W. D., & Wicker, P. A. (1998) · New England Journal of Medicine · doi:10.1056/nejm199805143382001 · Cited by 2,120
Treatment of Pulmonary Arterial Hypertension
Humbert, M., Sitbon, O., & Simonneau, G. (2004) · New England Journal of Medicine · doi:10.1056/nejmra040291 · Cited by 1,707
Harding, S. D., Sharman, J. L., Faccenda, E., Southan, C., Pawson, A. J., Ireland, S., Gray, A. J. G., Bruce, L., Alexander, S. P. H., Anderton, S., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1121 · Cited by 1,646
An L-arginine/nitric oxide pathway present in human platelets regulates aggregation.
Radomski, M. W., Palmer, R. M., & Moncada, S. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.13.5193 · Cited by 1,208
Andersson, K. E., & Wagner, G. (1995) · Physiological Reviews · doi:10.1152/physrev.1995.75.1.191 · Cited by 1,119
Self-citationBoolell, M., Mj, A., Sa, B., Gepi-Attee, S., Muirhead, G. J., Naylor, A. M., Ih, O., & Gingell, C. (1996) · PubMed · Cited by 1,067
Guanylate cyclase and the ⋅NO/cGMP signaling pathway
Denninger, J. W., & Marletta, M. A. (1999) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/s0005-2728(99)00024-9 · Cited by 1,040
Cited by
The Potential Role of Sildenafil in CancerManagement Through EPR Augmentation
Haider, M., Elsherbeny, A., Pittalà, V., Fallica, A. N., Alghamdi, M. A., & Greish, K. (2021) · doi:10.20944/preprints202104.0679.v1 · Cited by 42
Metadata
- Authors
- Andersson, K.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2018-04-25
- Volume
- 175
- Issue
- 13
- Pages
- 2554-2565
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2801518413
- Cited by
- 445
- References
- 63
- FWCI
- 19.85
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: PDE5 inhibitors – pharmacology and clinical applications 20 years after sildenafil discovery. https://app.cochat.ai/papers/10.1111/bph.14205
- The paper
- Andersson, K. (2018). PDE5 inhibitors – pharmacology and clinical applications 20 years after sildenafil discovery. British Journal of Pharmacology. https://doi.org/10.1111/bph.14205
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
